Cure Today

Delving into Subcutaneous Versus Intravenous Opdivo in Solid Tumors

Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. The Food and Drug Administration (FDA) approval of ...

Subcutaneous RYBREVANT® (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell ...

Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all ...
Monthly Prescribing Reference

Subcutaneous, Intravenous Abatacept as Potential Therapy for Polyarticular-Course JIA

hands of a child with juvenile idiopathic arthritis Researchers evaluated the efficacy and safety of abatacept in pediatric patients with polyarticular-course juvenile idiopathic arthritis. ATLANTA — ...
FierceBiotech

Subcutaneous Administration of Single-Agent VELCADE Demonstrates Efficacy Consistent with Intravenous Administration

ORLANDO, Fla.--(BUSINESS WIRE)-- Millennium: The Takeda Oncology Company today reported results from a randomized, international Phase III clinical trial comparing subcutaneous and intravenous ...
ascopubs.org

Subcutaneous nivolumab versus intravenous nivolumab in patients with previously treated, advanced, or metastatic clear cell renal cell carcinoma.

Phase 1a/b safety study of intravesical instillation of TARA-002 in adults with high-grade non-muscle invasive bladder cancer (ADVANCED-1). This is an ASCO Meeting Abstract from the 2022 ASCO Annual ...
Targeted Oncology

In a First, FDA Approves Monthly Subcutaneous Amivantamab for EGFR+ NSCLC

FDA approves monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced NSCLC, cutting clinic time and ...
Renal & Urology News

Subcutaneous Nivolumab Shows ‘Clinical Equipoise’ With IV Dosing in mRCC

A phase 3 trial demonstrated shorter administration times with subcutaneous vs IV delivery of nivolumab with no significant difference in mRCC progression-free survival. Subcutaneous administration of ...
Monthly Prescribing Reference

Subcutaneous, IV Trastuzumab Comparable for Breast Cancer

BCS: Radiological Tests Little Use in Detecting Breast Mets For human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, a subcutaneous formulation of trastuzumab is non-inferior ...
ascopubs.org

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary ...

Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium Authors retain all rights in any data supplements associated ...

New ECCO data show subcutaneous (SC) infliximab (Remsima™ SC) effectively recaptures and maintains disease control after drug holiday

Celltrion, Inc. today announced new data from a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), ...
Business Wire

Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
Medscape

Intravenous to Subcutaneous Infliximab Switch Shows Promise in IBD Management

Switching from established intravenous (IV) therapy to subcutaneous infliximab was associated with high treatment persistence, stable clinical disease activity, and consistent faecal calprotectin ...